Now that the patent has expired, this cancer drug is suddenly 99% cheaper
By Lucien Hordijk (editor until August 2022), | 24 March, 2022
The patent on the cancer drug Revlimid (lenalidomide) recently expired. Whereas a few weeks ago a pack still cost over 4,500 euros, after generic competition this is now only about 20 euros. This means that Dutch hospitals will save over 130 million euros.
Many of the main criticisms of the industry come together in this dossier: evergreening, price increases, shocking sales, and competition issues. Cellgene and Bristol Myers Squibb, respectively, raked in over €75 billion during the lifecycle of this product, according to an investigation by The Investigative Desk in collaboration with NRC.
Read the full article on NRC (in Dutch).
More investigations
Netherlands Health Council removes professor with ties to the liquor industry from advisory committee
Professor Joline Beulens, an internationally renowned lifestyle researcher working at the Amsterdam UMC, is no longer a member of the Health Council’s
Toxic Trains Dossier
This dossier is the result of a five months-long collaboration of five European journalists. Together, they investigated the transportation of ammonia
How the chemical industry doctored a new EU approval of a contested pesticide
There is growing evidence that glyphosate, the world’s most widely used weedkiller, carries serious risks for human health and the environment. Even s
This is the warning Big Alcohol wants to keep off your bottles of beer
Ireland was set to become the first EU country to put cancer warning labels on alcoholic drinks. But following a massive lobby campaign by Big Booze –
The hidden world behind illegal vapes
More and more Dutch young people are becoming addicted to vaping. This is not surprising, as illegal vapes with sweet flavors and excessive nicotine l
The Netherlands provides military resources to dubious regimes
Over the past decade, foreign trade ministers granted permits worth hundreds of millions for military exports to countries where there was a serious r
